Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women

By Ringe J. D.   Christodoulakos G. E.   Mellström D.   Petto H.   Nickelsen T.   Marín F.   Pavo I.  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2677-2687

Informa Healthcare

Access to resources Recommend Favorite

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis

By Sebba Anthony I.   Bonnick Sydney Lou   Kagan Risa   Thompson Desmond E.   Skalky Carol S.   Chen Erluo   de Papp Anne E.    

Current Medical Research and Opinion, Vol. 20, Iss. 12, 2004-12 ,pp. : 2031-2041

Informa Healthcare

Access to resources Recommend Favorite

Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis

By Devogelaer J.   Brown J.   Burckhardt P.   Meunier P.   Goemaere S.   Lippuner K.   Body J.   Samsioe G.   Felsenberg D.   Fashola T.   Sanna L.   Ortmann C.   Trechsel U.   Krasnow J.   Eriksen E.   Garnero P.  

Osteoporosis International, Vol. 18, Iss. 9, 2007-09 ,pp. : 1211-1218

Springer Publishing Company

Access to resources Recommend Favorite

Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women

By Kanis J.   Borgstrom F.   Johnell O.   Jonsson B.  

Osteoporosis International, Vol. 15, Iss. 11, 2004-11 ,pp. : 862-871

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis

By Palacios Santiago  

Current Medical Research and Opinion, Vol. 26, Iss. 7, 2010-07 ,pp. : 1553-1563

Informa Healthcare

Access to resources Recommend Favorite